methanesulfonic acid (R)-(7-fluoro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl ester | 1106941-36-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: methanesulfonic acid (R)-(7-fluoro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl ester
• 英文别名: [(3R)-6-fluoro-2,3-dihydro-1,4-benzodioxin-3-yl]methyl methanesulfonate
• CAS: 1106941-36-9
• 化学式: C₁₀H₁₁FO₅S
• 分子量: 262.259
• InChiKey: ISQLOBNDTXNADS-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  70.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methanesulfonic acid (R)-(7-fluoro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl ester 、 (S)-3-methyl-3-(2-(tetrahydropyran-2-yloxy)ethoxymethyl)piperidine 在 potassium carbonate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 1-((S)-7-fluoro-2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)-3-methyl-3-((S)-2-(tetrahydropyran-2-yloxy)ethoxymethyl)piperidine
  参考文献：
  名称：

  [EN] 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES
  [FR] DÉRIVÉS DE 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMÉTHYLE UTILISÉS EN TANT QU'ANTAGONISTES DES ALPHA2C POUR TRAITER DES MALADIES DES SYSTÈMES NERVEUX PÉRIPHÉRIQUE ET CENTRAL

  摘要：

  式(I)的化合物，其中X、Z、R1-R4和m如权利要求中所定义，具有α2C拮抗活性，因此可用于治疗外周系统和中枢神经系统（CNS）的疾病和症状。

  公开号：

  WO2009013390A1

文献信息

• 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES
  申请人：Din Belle David

  公开号：US20120035210A9

  公开（公告）日：2012-02-09

  Compounds of formula I wherein X, Z, R 1 -R 4 , and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.

  式I的化合物，其中X、Z、R1-R4和m如权利要求所定义，表现出α2C拮抗活性，因此可用作α2C拮抗剂。还公开了治疗外周系统和中枢神经系统疾病和病症的方法。
• 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES
  申请人：ORION CORPORATION

  公开号：US20130281486A1

  公开（公告）日：2013-10-24

  Compounds of formula I wherein X, Z, R 1 -R 4 , and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.

  式(I)的化合物，其中X、Z、R1-R4和m如权利要求中所定义，表现出α2C拮抗活性，因此可用作α2C拮抗剂。还公开了治疗外周系统和中枢神经系统疾病和病况的方法。
• 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous systeme diseases
  申请人：Din Belle David

  公开号：US08492549B2

  公开（公告）日：2013-07-23

  Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.

  公式I的化合物，其中X，Z，R1-R4和m的定义如权利要求中所述，具有α2C拮抗活性，因此可用作α2C拮抗剂。还公开了治疗外周系统和中枢神经系统疾病和病症的方法。
• 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES
  申请人：ORION CORPORATION

  公开号：US20140179926A1

  公开（公告）日：2014-06-26

  Compounds of formula I wherein X, Z, R 1 -R 4 , and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.

  式I的化合物，其中X、Z、R1-R4和m的定义见权利要求，具有alpha2C拮抗活性，因此可用作alpha2C拮抗剂。本文还揭示了治疗外周系统和中枢神经系统疾病和病症的方法。
• 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases
  申请人：Orion Corporation

  公开号：US08697723B2

  公开（公告）日：2014-04-15

  Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.

  公式I的化合物，在其中X、Z、R1-R4和m的定义如权利要求所述，表现出α2C拮抗活性，因此可用作α2C拮抗剂。还公开了治疗外周系统和中枢神经系统疾病和状况的方法。